Health News Releases

  • Today December 17
October 08, 2021 17:15
Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Response Predictability to Immuno-Oncology Drug Candidates
Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D
October 08, 2021 16:00
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worl
October 08, 2021 15:30
Introducing a New Antifungal Surveillance Program: Analysis of Resistance to Antifungals (ARIA) and Expanded Mycology Services at IHMA
International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifun
October 08, 2021 12:00
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to rec
October 07, 2021 14:10
SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic
October 06, 2021 17:40
Takeda Provides Update on TAK-994 Clinical Program
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immed
October 06, 2021 10:40
DentalMonitoring Launches the ScanBoxpro, the New Version of Their Patented Device to Maximize AI-powered Control of Dental and Orthodontic Care Anywhere, Anytime
DentalMonitoring, the company that pioneered artificial intelligence in dental and orthodontic care, is thrilled to announce the launch of the ScanBoxpro. Built upon the success of their previous D
October 06, 2021 09:35
Mawi DNA Technologies Announces Partnership with FUJIFILM
Mawi DNA Technologies (Mawi) has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to
October 05, 2021 17:20
BVI Announces Investment & Collaboration with Beyeonics Vision
BVI, a purpose-built diversified global ophthalmic device company, today announced an investment in Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT
October 05, 2021 16:30
Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
Merck, a leading science and technology company, today announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and safety of in
October 01, 2021 16:10
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and JCR Pharmaceuticals Co., Ltd. (TSE:4552) (“JCR”) announced today a geographically-focused exclusive collaboration and license a
October 01, 2021 08:23
ThoughtWire and Schneider Electric announce strategic partnership and new joint offering for healthcare facilities
Schneider Electric, the leader in the digital transformation of energy management and automation, and ThoughtWire, a leading provider of Digital Twins for the built environment, today announced a stra
September 30, 2021 17:30
RESTYLANE®, the Original Stabilized Hyaluronic Acid Filler, Celebrates 25 Years of Unmatched Achievement
Galderma, the world’s largest independent dermatology company, today marks the 25th anniversary of RESTYLANE®. The original non-animal stabilized hyaluronic acid filler restores, enhances and refreshe
September 30, 2021 17:00
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660,
September 30, 2021 15:40
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland Ch
September 30, 2021 14:30
Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud
The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and r
September 30, 2021 13:40
ANANDA Scientific and David Geffen School of Medicine UCLA Announce Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Med
September 30, 2021 11:30
Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis
Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 2
September 29, 2021 17:40
MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making
Managed Markets Insight & Technology (MMIT) and Evaluate, (a Welsh, Carson, Anderson & Stowe and Hg portfolio company)—which joined forces last month to become a $1.6 billion global pharma commercial
September 29, 2021 10:05
SpeeDx and SynGenis Partner for Custom Oligonucleotide Synthesis
SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partner
September 29, 2021 10:00
Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs
Medidata, a Dassault Systèmes company, recently named Rama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veterans, with Chilukuri as the founding president of Medidata Acorn AI and Kondru as
September 28, 2021 14:30
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authoriz
September 28, 2021 14:00
New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates
Masimo (NASDAQ: MASI) today announced the findings of a study published in the European Journal of Pediatrics in which Dr. Masashi Hotta and colleagues at the Osaka Women’s and Children’s Hospital in
September 28, 2021 12:00
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without t
September 24, 2021 18:35
IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide mor
25 per page50 per page75 per page100 per page